Venn: Your partner in Drug Development and Resourcing Solutions
Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management. This enables us to create, plan and execute drug and medical device development programs effectively and seamlessly for our clients. We have dedicated operations in Ireland, France, Germany, the Netherlands, the UK, the US, and European-wide representation.
Rare 2017 is the 5 th edition of meetings held every 2 years in France to promote a health policy and research at the service of
Rare 2017 is the 5 th edition of meetings held every 2 years in France to promote a health policy and research at the service of people with rare diseases, with an undeniable success over the years.
Founded by EuroBioMed and launched this year by the Rare Maladies Foundation, the Rare meetings bring together all stakeholders : public decision-makers, patient representatives, health and research professionals, pharmaceutical manufacturers, medical devices and healthcare technologies. They are designed to be a laboratory of ideas and analyzesto move towards a more equitable and effective health system, more knowledge for health decision-making, innovations to meet unmet needs, and more quality of life for patients and their families. These lines of thought will structure the debates to identify where we are, what remains to be done and how to do it. Each axis will be presented in a didactic way to present the current situation and the challenges of the future. This will be followed by a debate with key stakeholder representatives and an exchange with the participants.
We invite you to learn from renowned pioneers in the field of immuno-oncology and to pivot in our network of open innovation and collaboration during our five year
We invite you to learn from renowned pioneers in the field of immuno-oncology and to pivot in our network of open innovation and collaboration during our five year anniversary Pivot Oncology Conference. During their key-notes (inter)national speakers will focus on breakthroughs in precision medicine used for cancer treatment from both the scientific and business perspective. In the satellite sessions Pivot Park based companies will inform you on the latest developments and breakthroughs in their specific field of expertise.
For more information on the Pivot Oncology Conference event: Click here
As a reminder, the Club Phase 1 organizes its annual workshop on Thursday November 23rd, 2017 which will take place at « la Maison de la Chimie » in Paris
As a reminder, the Club Phase 1 organizes its annual workshop on Thursday November 23rd, 2017 which will take place at « la Maison de la Chimie » in Paris from 13:30 to 16:30.
The objective of this workshop will be to exchange and discuss on the very recent EMA guideline on the early clinical trials (July 2017). This guideline represents a very important tool for the specialists in early clinical trials. Several speakers (CIC representative, CRO representative, Oncology representative, Pre-clinical representative) will present their perspectives. In addition we are pleased to inform you that representatives from ANSM will be present during this meeting which is a very good news for our activity and perspective.
This workshop will be free for the members of our association. Due to limited number of places, we encourage you to register as soon as possible.